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Chapter 1

Regulation of IFN-γ Expression
John Fenimore and Howard A. Young

Abstract Interferon gamma, referred to here as IFN-γ, is a major component in
immunological cell signaling and is a critical regulatory protein for overall immune
system function. First discovered in 1965 (Wheelock Science 149: (3681)310–311,
1965), IFN-γ is the only Type II interferon identiﬁed. Its expression is both positively and negatively controlled by different factors. In this chapter, we will review
the transcriptional and post-transcriptional control of IFN-γ expression. In the transcriptional control part, the regular activators and suppressors are summarized, we
will also focus on the epigenetic control, such as chromosome access, DNA methylation, and histone acetylation. The more we learn about the control of this regulatory protein will allow us to apply this knowledge in the future to effectively
manipulate IFN-γ expression for the treatment of infections, cancer, inﬂammation,
and autoimmune diseases.
Keywords IFN-γ • Transcriptional control • Epigenetic control • LncRNA •
MicroRNA • Activator • Suppressor

1.1

Introduction

Interferon gamma, referred to here as IFN-γ, is a major component in immunological cell signaling and is a critical regulatory protein for overall immune system
function. First discovered in 1965 [1], IFN-γ is the only Type II interferon identiﬁed. Functionally it is a homodimer with an antiparallel interlocking structure, lacking beta sheets but possessing six alpha helixes per monomer. In humans the IFN-γ
gene is found on chromosome 12q15 [2] and in mice on chromosome 10D2 [3]. The
human gene for IFN-γ has four exon regions and three intron regions, covering 4.04
kbps [4]. The receptor complex for IFN-γ, IFNGR1 and IFNGR2, is almost
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ubiquitous in all mammalian cells, save erythrocytes. In addition, the structure of
IFN-γ is much conserved in studied jawed vertebrates [5].
IFN-γ’s effects on cells are notable, having been shown to modulate the expression of over 2,300 human genes [6]. While of the functions of different interferons
are often redundant, a lack of normal IFN-γ expression is linked with cases of
heightened weaknesses to some diseases even in the presence of other interferons.
As discussed by Kaufmann and Booty et al. [7, 8], when expression of IFN-γ is low,
susceptibility to mycobacterial and fungal infections is common; this shows the
need for IFN-γ expression to ﬁght disease and depicts the nonredundant functions
of IFN-γ’s maintenance of host resistance [7–10].
Unlike other interferons, even though IFN-γ does possess an antiviral capacity, it
is more notable for its broader ability to stimulate and modulate the immune system.
IFN-γ triggers the immune responses that lead to phagocytosis and increased
expression of the MHC receptors on the surface of cells. This is further highlighted
by IFN-γ being used to treat chronic granulomatous diseases, a group of inherited
immune disorders in which white blood cells fail to control bacterial infections, thus
causing severe infections in the skin, liver, lungs, and bone as pathogens are contained in granules, but not consumed via phagocytosis [7]. In turn the presence of
high amounts of IFN-γ has been linked to inﬂammation. In some diseases such as
multiple sclerosis, an autoimmune disease involving inﬂammation in the brain and
spinal column, IFN-γ was present in abnormally high levels in affected tissues [12].
IFN-γ has also been found to be involved in other chronic diseases such as Type 1
diabetes, where IFN-γ overexpression has been linked to autoimmune dysfunction,
as inﬁltration by T cells expressing IFN-γ into islets containing pancreatic beta cells
results in destruction of beta cells [13, 14].
The activity of IFN-γ is noted as being involved in the activation, growth, and
differentiation of T cells, B cells, macrophages, natural killer (NK) cells, and other
cell types such as endothelial cells and ﬁbroblasts, thus making it vital to the inﬂammatory response and to cell-mediated immune responses [4]. The innate and adaptive immune systems rely on controlled IFN-γ expression to preserve the balance
between an effective host immune response and the development of autoimmune
disease. For this reason, it is very important to understand the pathways that regulate
the expression of IFN-γ.

1.2

Transcriptional Controls

IFN-γ gene expression is controlled by a very complex system of regulation. IFN-γ
has been noted to be normally expressed by cells from the immune system, such as
the natural killer, or NK, cells and natural killer T, or NKT, cells which are both
involved in the innate immune response. IFN-γ is also expressed during adaptive
immune responses via CD4+ Type 1 helper (Th1) T cell, or CD4+ cells, and CD8+
cytotoxic T lymphocyte effector cells, or CD8+ cells. The expression of IFN-γ is one
of the deﬁning traits of CD4+ Th1 cell-type immune cells [11]. The differentiation
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of immune cells into cells that produce IFN-γ or inhibition of such differentiation is
also inherent to the amount of IFN-γ that is expressed by a host undergoing an
immune response. Production of IFN-γ is controlled at several levels, including
epigenetic changes, chromosomal access, cell surface signaling, transcription factor
binding to promoters and enhancers, mRNA stability, and long noncoding RNA
(LncRNA) interactions with the IFN-γ locus. Given the importance of IFN-γ to host
immune function, it is not surprising that this single gene is regulated at many different levels.
Some regions of the genome are noted as being important for the control of
IFN-γ expression in speciﬁc cell types but not in others. For instance, the region
92–18 bp upstream of the start of transcription is noted as being vital for expression
in human T cells and NKT cells, but not NK cells [15]. More work, illuminating the
progress of our understanding of IFN-γ epigenetics, has demonstrated the importance of conformational changes to the structure of the IFN-γ locus and factors that
affect access to the site [16–18]; this shows there are multiple mechanisms impacting the transcription of this gene.

1.2.1

Epigenetic Control

The role of access to and control of genetic information is an important factor when
discussing the process of transcription. The IFN-γ gene is no exception, with several
methods of epigenetic control affecting gene expression. However understanding
the speciﬁc details of this control is a developing science. Speciﬁc areas of conserved noncoding sequences, or CNS, are vital for the expression of IFN-γ as relevant CNS regions are present before and after the transcription start site. Of great
interest is the difference between their roles in different cell types. For example, it
has been reported that CNS-30 can be deleted from NK cells without a loss of IFN-γ
expression, while other cells that express IFN-γ require it for full transcription [15].
T cells require the presence of CNS-2, and all NKT and some T cells require the
CNS present at +20 [17]. NK cell gene expression may also be enhanced by access
to CNS-2 and CNS+20, but these regions are not required for basal IFN-γ gene
expression [17]. Alternatively, CNS-16 has different effects depending upon the cell
type; in NK cells it upregulates the expression of IFN-γ, but it is not required for
transcription, while in the CD4+ Th2 cells, suppression of IFN-γ expression requires
this region [17].

1.2.1.1

Chromosomal Access/DNA Methylation/Histone Acetylation

Chromatin condensation, by preventing or allowing access to the promoter or other
regulatory elements of a gene, is a ﬁrst step in controlling gene expression. With
respect to IFN-γ, expression is regulated ﬁrst via chromatin modiﬁcation. This is
shown by the differences between nonactivated T cells and activated T cells with
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regard to the chromatin density around the IFN-γ gene [17]. The compression of the
IFN-γ region has a marked difference when comparing Th1, Th2, and naïve T cells,
as observed from a chromatin conformational capture assay [16]. This is also apparent in NK cells, which also have low chromatin density around the transcription
start site indicating easier access to the promoter for binding of the required transcription factors and RNA polymerase [17].
Additional regulation of the expression of IFN-γ comes in the form of DNA
methylation, which occurs when cytosine is converted to 5-methylcytosine at CpG
nucleotides, and as a result prevents direct interactions with speciﬁc transcription
factors to those regions of the DNA. The IFN-γ CNS-34, IFN-γ CNS-22, the IFN-γ
promoter, and IFN-γ CNS+29 are methylated in naïve T helper cells, and methylation is lost as T helper cells progress through their differentiation pathways [19, 20].
The difference in methylation of DNA is notable in cells that do not express IFN-γ,
where the locus is highly methylated, indicating that the methylation of speciﬁc
transcription factor binding sites is an additional mechanism of transcriptional control. Contrasting this, hypomethylation, which is observed between the −200 and
+1 positions of the IFN-γ promoter, contributes to the expression of the gene in
activated Th1 and NK cells, through binding of transcription factors to those regulatory regions [20]. A target for methylation is a SnaBI restriction enzyme recognition
site that is highly conserved in all species and is present at −52 bp in the IFN-γ
promoter [17, 18]. Demethylation of this SnaBI site is rapid during the processes of
antigen activation, differentiation, and proliferation of T cells [17]. Of importance
NK cells do not have notable methylation at this site, and in NK cells, cytokine
stimulation of IFN-γ expression (e.g., IL-12) results in the rapid demethylation of
the broader IFN-γ locus [17].
Histone acetylation, another method of restricting transcription of a gene, is a
reversible modiﬁcation of DNA that regulates chromatin access. Histone acetylation of the IFN-γ locus is of interest because when naïve T cells are initially stimulated, the loci for the IFN-γ and IL-4 genes are unpacked by histones [17]. The
process of histone acetylation changes after differentiation, with 50 kb of DNA both
up- and downstream from the IFN-γ locus being closed off in non-IFN-γ expressing
CD4+ Th2 cells [17]. This can also be observed by depriving the activated Th1 cells
of STAT4, thus suggesting that active binding of STAT4 driven by IL-12 is critical
for maintaining an open chromatin conformation at the IFN-γ locus [22].
Additionally, in T cells it has been shown that chromatin conﬁrmation is driven
through an interplay of T-cell-speciﬁc T-box transcription factor (T-bet) and GATA3,
which are transcription factors we will discuss later in this chapter. T-bet notably
keeps the area where IFN-γ is located accessible via histone acetylation, while
GATA3 seems to prevent the action of T-bet in keeping the IFN-γ locus accessible
[17, 18]. This interaction between T-bet and GATA3 is notably absent in NK cells
as the CNS regions that impact IFN-γ gene expression have, even in the absence of
stimulation and active transcription, similar histone-acetylated domains as compared to that found in activated T cells [18].
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Chromatin Positioning

Chromatin may form blocks to transcription or contrastingly cause speciﬁc areas of
DNA to be more accessible; this is done not only via compression but also via moving elements away or toward enhancers. Chromatin may also cause movement in the
three-dimensional space the gene occupies to prevent the association of transcription factors or to facilitate such binding, via chromatin looping. This accessibility is
observed via a notable change in the conformation of the IFN-γ locus [16]. CCCTCbinding factor, or CTCF, is a zinc ﬁnger transcription factor that binds the core
CCCTC sequence [21]. These proteins have been described as suppressors for
which there are three binding sites across the IFN-γ gene locus. These sites have
been deﬁned as markers that have been used to denote the limits of this locus [22]
and have also been depicted to create a loop in active T cells which has been hypothesized to be required for protection of the gene from heterochromatin silencing and
to increase the efﬁciency of expression [17].

1.2.1.3 LncRNAs
Long noncoding RNAs, or lncRNAs, are noted as being inhibitors of transcription
via interactions between sections of RNA greater than 200 bp that are transcribed
alongside other regions of chromatin that link to and inhibit the action of proteins
and RNA. The role of these lncRNAs in the enhancement or suppression of transcription is a developing ﬁeld of study as their activity is becoming more deﬁned.
For example, the ncRNA repressor of the nuclear factor of activated T cells, or
NRON, is a negative regulator of the transcription factor (NFAT), which interacts
with the IFN-γ promoter [23]. This inhibition of NFAT by NRON is caused by the
formation of protein and RNA complexes, resulting in sequestration of NFAT in the
cytosol, away from the DNA [23]. It has also been reported that Theiler’s murine
encephalitis virus possible gene 1, or TMEVPG1, also named nettoie Theiler’s pas
Salmonella, or NeST, is the ﬁrst identiﬁed lncRNA to regulate expression of IFN-γ
[24]. NeST is located 170 kb downstream from the IFN-γ gene and transcribed from
the antisense strand relative to IFN-γ; the 33 kb NeST gene is spliced into a 1.7 kb
RNA transcript in human cells [24]. Studies have shown that NeST’s expression in
both mouse and human is Th1 T-cell selective and dependent on STAT4 and T-bet
[24]. Due to this pattern of expression and its structural traits, it is believed that
NeST associates with WD repeat-containing protein 5, or WDR5, to promote histone H3 lysine 4, drive methylation to enhance chromatin accessibility, and conversely decrease attraction of local histones at the nearby IFN-γ locus, thus
promoting transcription [17].
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1.2.1.4

miRNAs

MicroRNAs, or miRNAs, are between 18 and 25 nucleotides long and are noncoding RNAs that suppress gene expression by binding to the 3′ UTR of target genes,
resulting in either translation inhibition or mRNA degradation. A broader role for
miRNA control of IFN-γ expression was demonstrated by studies demonstrating
that the elimination of the Dicer gene, vital for the processing of microRNAs,
increased the expression of IFN-γ in T cells [25]. Interestingly this effect has been
noted in CD4+ TH2 cells indicating that there may be some changes to the epigenetics in the cells as a result of the inhibition of miRNA processing [25].
Recently studies have shown that the miRNA, miR-223, which is notably
enhanced by estrogen, positively regulates the expression of IFN-γ via inhibition of
anti-inﬂammatory elements such as IL-10 [26]. In other studies, microRNA-146a
and microRNA-146b both suppress the activity of TRAF6 and IRAK1 protein
expression, factors that are important for the function of the IFN-γ promoter, and
thus cells expressing these miRNAs show decreased IFN-γ expression [27, 28].
Studies have also shown that miR-29 suppress IFN-γ production by directly targeting IFN-γ mRNA and enhancing its degradation [29]. However contrasting experimental evidence reports that miRNA-29 inhibition is driven via degradation of the
T-box transcription factor T-bet mRNA instead of the IFN-γ mRNA [30]. Additional
studies focused on miR-155 have shown that in NK cells this miRNA increases the
expression of IFN-γ when NK cells are stimulated, notably by both IL-18 and IL-12
[31]. miR-155 is observed having its own expression increased when the NK cells
are stimulated with IL-18 and IL-12 via downregulating SHIP1, a phosphatase, that
in turn suppresses NF-kB activity, a transcription factor known to bind to the IFN-γ
locus and stimulate transcription [31, 32].

1.3

Inducers of IFN-γ

IFN-γ is part of a system of biological signals that can induce substantial changes
inside the cell and in the host overall. As such it must be regulated, since it is not
passively expressed and different signals regulate expression either by enhancing or
inhibiting gene expression. These signals come in many forms, but the primary
methods are dependent upon cell activation through signaling via cell surface receptors. Regulation of IFN-γ expression is largely driven by activators like transcription
factors such as T-bet and NFAT and speciﬁc inhibitors, like TGF-beta, in CD4+ Type
1 helper T cells. Methods to manipulate this upregulation involve speciﬁc systems
using phosphorylation of transcription factors, driven by activation of multimeric
receptors of cytokines linked to Janus kinases (JAK) activation, while inhibitory
signals act through inhibition of these signaling cascades and their receptors resulting in inhibition of the speciﬁc transcription factors required for IFN-γ transcription
[33–37].
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Fig. 1.1 The archetypal motif of the receptor and cytokine structure to stimulate STATs. The
interaction of a cytokine causes the dimerization of surface receptors which in turn cause
phosphorylation-driven changes which cascade to affect transcription

1.3.1

IL-2

IL-2 is a cytokine with three surface receptor subunits, alpha, beta, and a common
gamma chain. The presences of these receptor subunits determine the level of afﬁnity in each immune cell type for gene activation. For example, the beta and gamma
chains together form a complex that binds IL-2 with intermediate afﬁnity on NK
cells, while all three receptor chains form a complex that binds IL-2 with high afﬁnity on activated T cells [33]. The stimulated signaling pathways upregulate IFN-γ
expression but also notably upregulate the expression of SOCS1 which functions to
prevent overexpression of IFN-γ [38]. Suppressor of cytokine signaling, or SOCS1,
is a suppressor of IFN-γ expression that interacts with the tyrosine kinase (TYK),
Jak1, and inhibits expression downstream by reducing STAT phosphorylation [33].
IL-2 is also noted for triggering the binding of a STAT5 a/b heterodimer to a
STAT5-binding element −3.6 kb from the transcription start site of the IFN-γ gene
[39, 40] (Fig. 1.1).

1.3.2

IL-12/STAT4

Interleukin 12, or IL-12, is a cytokine heterodimer that can induce IFN-γ transcription and cause nuclear accumulation of IFN-γ mRNA in CD4+ T helper cells and
NK cells. At activation, two subunits of the IL-12 receptor which is a heterodimer
comprised of the beta-1 and the beta-2 chains of the receptor come together to activate the receptor-associated Janus kinases, JAK2 and TYK2 [33, 40]. STAT4 is then
phosphorylated by these tyrosine kinases and translocated into the nucleus to activate gene transcription. The pSTAT4 then interacts with IRF-1 and ERM to activate
their binding to the IFN-γ promoter [14, 41, 42]. This activation also takes place in
NK cells and is independent of most other forms of IFN-γ stimulation [23]. IL-12

J. Fenimore and H.A. Young

8

has been noted to be dependent on STAT4 to induce expression of IFN-γ as STAT4
is critical for maintaining an open chromatin conformation at the IFN-γ locus [17,
43]. Furthermore transcriptional activity of T-bet, induced by IFN-γ, appears to
increase the expression of IL-12 receptor beta 2 [43], thus demonstrating a feedback
loop that enhances the cell response to IL-12.
IL-12 stimulation of cells results in an accumulation of IFN-γ mRNA in the
nucleus, and release of this accumulated IFN-γ mRNA into the cytoplasm is drastically increased by the presence of interleukin 2, or IL-2 [44]. It has been hypothesized that this increased release of mRNA may be a form of priming cells to release
more IFN-γ mRNA when they encounter a second signal, creating a method of
regulation that prevents overexpression but allows the cell to have a strong response
when needed. It has been shown that both IL-2 and IL-12 in combination promote a
steady release of IFN-γ over time, notably more than either signal alone, thus demonstrating a synergistic response of the cell when multiple activating signals are
encountered [44].
These previously described pathways of IFN-γ expression when CD4+ cells are
stimulated by IL-12 can occur only if the T-bet binding region is not blocked by the
dual zinc ﬁnger transcription factor, GATA-binding protein 3 or GATA3 [45]. The
GATA3 transcription factor does not affect the IFN-γ promoter region directly, but
instead affects the downregulation of STAT4, thus preventing signaling needed to
induce IFN-γ expression. GATA3 is in turn shown to be stimulated by exposure of
a naïve T cell to interleukin 4 [45].
STAT3 has been reported to have variable effects in NK cells and their expression of IFN-γ. It has been noted that STAT3 regulates IFN-γ production by binding
the IFN-γ promoter upon stimulation of IL-12. However STAT3 has not been shown
to be required for IFN-γ expression by NK cells [46, 47].
It is important to note the synergistic effect of cytokines in regard to IFN-γ gene
expression. A very strong synergy between IL-12 and IL-18 for IFN-γ expression is
driven by the upregulation of receptors on cells that have been exposed to one or the
other cytokines; the IL-12 beta-2 receptor chain has been noted to be upregulated by
IL-18 and IL-12 can upregulate the IL-18 alpha receptor chain [48, 49], thus stimulating the target cell to be maximally responsive to these cytokines.

1.3.3

IL-15

Interleukin 15, or IL-15, is a heterodimeric cytokine that triggers IFN-γ gene expression through binding to a heterodimeric IL-15 receptor [35]. Signaling occurs
through Janus kinases Jak 1 and Jak 3 activation which in turn phosphorylates
STAT3 and STAT5. Studies have shown the responsiveness of CD8+ cells to IL-15
results in the maintenance of CD8+ T-cell survival, thus affecting the host’s overall
production of IFN-γ [35, 41].
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IL-18

A member of the IL-1 family, interleukin 18 (IL-18) (originally designated interferon gamma-inducing factor), induces the transcription of IFN-γ. The surface
receptors of IL-18 are well characterized; the receptors are heterodimeric with a
region for the binding of the ligand, the IL-1 receptor-related protein (IL-1Rrp), and
the signal transducing subunit or the accessory protein-like subunit (AcPL) [36].
Once activated, this causes a signal cascade involving MYD88, the IL-1 receptorassociated kinase (IRAK), TNF receptor-associated factor 6, and the nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB) [34]. NF-kB is shown to
bind and enhance activity of the IFN-γ promoter, increasing expression of IFN-γ
[50]. NF-kB additionally undergoes a chain of interactions to stimulate the activation of STAT4 which stimulates the production of IFN-γ [52, 53].
Interleukin 10 (IL-10) is characterized as inhibiting the function of NF-kB and
thus is considered an inhibitor of IFN-γ expression [54].

1.3.5

IL-27/STAT1/STAT3

Interleukin 27 (IL-27), a heterodimeric cytokine from the IL-12 family, enhances
IFN-γ production by activated T cells and NK cells [33]. One such induction of
expression is activated via IL-27’s interactions with a dimeric receptor comprised of
the interleukin-27 receptor alpha chain (IL27Ra) and glycoprotein 130 (gp130)
[55]. Upon binding of IL-27 to this receptor, two arms of Janus kinases are activated: Jak1 linked to the IL27Ra and Jak2, Tyk2, and Jak1 linked to gp130 [55].
Triggering the phosphorylation of STAT1 and STAT3, this causes the transport of
the pSTAT1/3 heterodimer to the nucleus where it activates the T-bet promoter,
resulting in increased T-bet and subsequent IFN-γ expression [55, 56].

1.4

Positive Transcriptional Control Factors

IFN-γ production is highly variable and cells do not express IFN-γ in a resting state.
Thus there are numerous methods to activate immune cells to express this cytokine
and vary its levels of expression. These controls are driven by transcription factors
that form complexes on speciﬁc regions of DNA to control the level of transcription
via RNA polymerase 2 [57]. In this section we will discuss the transcription factors
involved in regulating IFN-γ expression and brieﬂy summarize our understanding
of their activation and activity (Fig. 1.2).
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Fig. 1.2 The IFN-γ gene, depicting general structure and relative locations of protein-binding
sites

1.4.1

T-bet

T-bet, or the T-cell-speciﬁc T-box transcription factor, is considered one of the most
important controls for the expression of IFN-γ. T-bet has been deﬁned as a key factor in T-cell differentiation and is expressed in many cell types in the immune system. However in many regards, it has been seen as the endpoint that other signal
pathways must reach to stimulate the expression of IFN-γ or as the target that needs
to be blocked to prevent expression [58]. Recent studies have shown T-bet is required
for IFN-γ production and lineage commitment of CD4+ T cells, but not of CD8+ T
cells [45]. Using T-bet KO mice, it was shown that, when stimulated, CD4+ T cells
had a profound deﬁciency in IFN-γ expression [59]. Contrastingly it was determined there is little difference in IFN-γ expression in stimulated CD8+ cells with or
without T-bet [59]. Furthermore IL-12 has also been noted to induce T-bet in an
IFN-γ receptor and STAT1-independent manner in CD8+ T cells [60]. Induction of
T-bet results in upregulation of IL-12RB2, a receptor essential for responsiveness to
IL-12, and differentiation to a CD4+ Th1 cell type [34]. However studies have
shown that T-bet represses the Th2 lineage commitment through a tyrosine kinasemediated interaction that interferes with the binding of GATA3 to its target DNA
[61]. Making T-bet both a suppressor and an enhancer depending on the perspective
of Th1/Th2 T-cell determination indicates that T-bet has a broader inﬂuence on
chromatin structure that directly and indirectly impacts IFN-γ gene expression [17].
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Eomes

In CD8+ T cells, the primary driver of IFN-γ expression is via the transcription factor Eomesodermin (Eomes), which functions independent of T-bet [62]. However it
has been reported that there is synergistic effect when both Eomes and T-bet transcription factors are expressed [63]. The activity of Eomes was also noted to increase
phosphorylated STAT4 in CD8+ T cells, further promoting IFN-γ transcription [64].
Experiments with T-bet−/− CD8+ T cells have demonstrated normal IFN-γ expression, while Eomes −/− CD8+ cells did not express IFN-γ at notable levels, indicating a critical role for Eomes in CD8+ T-cell IFN-γ transcription [62, 63].

1.4.3

AP-1/CREB/ATF-2

Activating promoter 1, or AP-1, has been linked to the activity of the IFN-γ promoter [64]. AP-1 has been reported to enhance the activity of NFAT proteins through
the formation of complexes with these transcription factors [42].
It has been shown that c-Jun, cAMP response element-binding protein (CREB),
and ATF-2 are essential for activation-induced transcription of IFN-γ, and c-Jun
binds preferentially to the IFN-γ proximal element at -52 as a heterodimer with
ATF-2 [42]. The c-Fos and c-Jun transcription factors form a heterodimer known as
activator protein 1 (AP-1), part of a subset of a large family of transcriptional control proteins, which in turn forms another complex with NFAT [65]. CREB or cAMP
response element-binding protein is a known transcription factor closely associated
with AP-1 that has been shown to bind to the proximal IFN-γ promoter −73 to −48
bp upstream of the transcription start site [64]. This strongly implicates the involvement of CREB proteins in the regulation of IFN-γ expression [65].

1.4.4

NFAT

Nuclear factor of activated T-cell (NFAT) binding sites have been identiﬁed at positions −280 bp to −270 bp and −160 bp to −155 bp upstream from the IFN-γ transcription start site, and studies show that they are required for full activity of the
IFN-γ promoters in T cells [42, 66]. This effect is documented by experiments that
demonstrated decreased levels of expression by full-length IFN-γ promoter-reported
constructs with promoter regions that contain mutations in one or both of the NFATbinding sites [66, 67].
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1.5

Negative Transcriptional Controls

Overexpression of a speciﬁc signal can lead to drastic problems in all biological
systems. In the immune system, such overexpression of a speciﬁc gene can cause
autoimmune responses that can have far-reaching consequences to a host. IFN-γ is
a powerful immunoregulator and the ability to turn the signal off is in many ways
just as important as its activation. While not as fully understood as activating signals, characterization of the inhibitory signals leading to decreased expression of
IFN-γ is proving vital to our understanding of the regulation of this gene.

1.5.1

Homeobox/Prox1

Prospero-related homeobox (Prox1) is a suppressor of the expression of IFN-γ in T
cells; however, it does not typically function to suppress the genes as a homeobox
gene would normally be expected to function. It has been reported that Prox1 does
not bind to the promoter region of IFN-γ but that it uses a method of facilitating a
conformational change with a protein intermediary to inhibit the synthesis of IFN-γ
mRNA [68]. The nuclear receptor peroxisome proliferator-activated receptor
gamma (PPARγ) has been shown to link to the Prox1 structure and inhibit IFN-γ
expression [68]. The presence of Prox1 however is also notably downregulated as
the cell differentiates into a CD4+ T cell, but the mechanism is unknown [68].
PPARγ and PPAR delta have also been reported to inhibit IFN-γ gene expression in
part by antagonizing the activities of the transcription factors AP-1, STAT, and
NF-kB [69, 70]. However, once IFN-γ has been expressed, it has been demonstrated
to in turn suppress PPARγ expression via upregulation of activated STAT1 [71],
thus forming a regulatory cycle to prevent under- or overexpression.
IFN-γ has been linked to many sex-biased autoimmune diseases and the sex bias
in PPARγ coincides with these phenomena [72]. Males have a notably higher level
of expression of PPARγ than females, thus contributing to the ﬁnding that female
mice and women express more IFN-γ than their male counterparts [72].

1.5.2

TGF-B

Transforming growth factor beta (TGF-B) is a superfamily of cytokines that, when
activated, downregulate the expression of T-bet mRNA via direct interaction of
SMAD proteins with the T-bet promoter [73]. TGF-β utilizes SMAD2, SMAD3,
and SMAD4 to suppress IFN-γ via inhibiting the activity of T-bet by binding to the
proximal T-bet site in the IFN-γ locus [74].
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DREAM

Downstream regulatory element antagonist modulator (DREAM) can directly bind
to the IFN-γ promoter and inhibit transcription. DREAM forms a complex with the
related protein KChIP-2 around an area downstream of the TATA box in the IFN-γ
promoter [75]. DREAM’s binding takes place as a doublet with one direct and one
inverted downstream regulatory element located at position +20 downstream from
the transcription initiation site if IFN-γ, thus blocking transcription [75]. DREAM
is constitutively expressed in unstimulated T lymphocytes, and it has been reported
that DREAM is rapidly downregulated after stimulation of T cells [75]. This suggests DREAM may be important to prevent basal expression of IFN-γ when immune
cells are not stimulated and are in a resting state.

1.5.4

GATA3

Transacting T-cell-speciﬁc transcription factor GATA3 is a potent suppressor of
IFN-γ and has effects on T-cell differentiation. Members of the CREB/ATF, AP-1,
octamer 1, and GATA families of transcription factors bind to the proximal −70 bp
to −47 bp and distal −98 bp to −72 bp regions upstream from the start site of IFN-γ
transcription [76]. It has been reported that GATA3 restricts access to the promoter
regions of IFN-γ and T-bet, thus preventing interactions of activating transcription
factors with the IFN-γ promoter [76]. In addition, Gata3 and octamer 1 enhance the
expression of IL-4-driving cell differentiation away from a state where IFN-γ is
expressed [77].
Published reports have promoted the idea that even though the binding of GATA3
can be detected at two GATA motifs, in positions −108 bp to −91-bp, of the human
IFN-γ gene, it may be that the lack of expression of IFN-γ in the presence of GATA3
is more notably driven by the suppression of other transcription factors [76, 78]. Of
note, there was a reduction in STAT4, involved in promoting IFN-γ transcription, in
the presence of high levels of GATA3 [76]. Interestingly, these studies also showed
a reduction of the amount of STAT1 in the cells expressing elevated levels of GATA3
[78]. In addition, runt-related transcription factor 3 (Runx3) enhances the binding of
T-bet to the IFN-γ locus by binding to speciﬁc regions in the IFN-γ promoter; this
in turn decreases the binding frequency of GATA3 [79]. The binding of T-bet acts to
competitively suppress GATA3 binding, thus enhancing IFN-γ transcription [79,
80]. GATA3 has also been linked to changes in histone modulation, promoting
access to some areas and restricting access to others in competition with T-bet [76].
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1.5.5

Yin Yang 1

Ying Yang 1, or YY1, is a zinc ﬁnger transcription factor that belongs to the human
GLI-Kruppel family of nuclear proteins and is an inhibitor of the IFN-γ promoter in
two notable models [81]. There are two constitutive YY1-binding sites in the IFN-γ
promoter at positions Y1 −199 bp to −203 bp and Y2 −217 bp to −221 bp upstream
from the transcriptional initiation site [81]. These sites are both hypothesized to
play a role in inhibiting the expression of IFN-γ by competition for DNA binding
with AP-1 at the Y1 position [64] and by activation of an AP-2-like protein by YY1
binding at the Y2 position which then acts as a repressor of IFN-γ transcription [81].

1.6

Posttranscriptional Regulation

Posttranscriptional downregulation of IFN-γ is mostly characterized as being from
processes degrading the IFN-γ mRNA. Removing the region in the 3′ UTR that
contains the AUUA repeat elements (ARE) results in signiﬁcantly higher levels of
expression of IFN-γ due to stabilization of the mRNA [82]. A second method of
control involves the 5′ UTR region of the mRNA. As the structure of the 5′UTR has
revealed the presence of a semi-knot, this structure triggers a natural anti-dsRNA
reaction by RNA-activated protein kinase (PKR) which helps downregulate the continued expression of IFN-γ via binding to the mRNA and facilitating degradation of
the dsRNA present in the semi-knot [83, 84].
There are other forms of posttranscriptional controls for IFN-γ. A mechanism by
which IFN-γ is posttranslationally modiﬁed, i.e., glycosylation at positions 25 and
97, stabilizes the protein and protects it from degradation [85]. In response to stress,
the host cell can also change the protein’s ﬁnal structure, by downregulating the
expression of the enzyme, Furin, which is needed to generate the IFN-γ protein into
a functional state by cleaving the leader peptide [86]. This demonstrates that controlling functional expression of this cytokine is a continuum of mechanisms that
extend beyond the domain of transcription alone.

1.7

Conclusions

Negative and positive controls of IFN-γ expression must remain in balance to prevent the promotion of autoimmune diseases or host deﬁciencies in ﬁghting disease.
The conserved nature and the wide-ranging effects of IFN-γ on the adaptive and
innate immune systems ensure that the expression of IFN-γ is a potent response
required to ﬁght disease, but one that must be controlled in healthy hosts. This control is transcriptionally regulated at the level of chromatin access involving chromatin secondary and tertiary structure, DNA methylation, and histone acetylation. This
process is in turn effecting and affected by transcription factors, which are both
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activators and inhibitors of gene expression. The speciﬁc host factors can be shaped
by the process of transcription itself, as impacted by extracellular signals received
by the target cells and RNA stability following gene induction. Understanding the
labyrinthine system of controls may seem daunting, and the complete picture of
IFN-γ control is still a point of active investigation. However, the more we learn
about the control of this regulatory protein will allow us to apply this knowledge in
the future to effectively manipulate IFN-γ expression for the treatment of infections,
cancer, inﬂammation, and autoimmune diseases.
(The author would like to apologize for any articles or work that was missed in
the collection of this work. The volume of data, space, and time constraints made it
impossible for the author to create a complete list of the valuable research that has
been done on this integral part of immunological research.)
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